Acrivon Therapeutics Inc (NASDAQ:ACRV) currently has a daily average trading volume of 48.77K but it saw 1849622 shares traded in last market. With a market cap of 81.26M USD, the company’s current market price of $2.61 came falling about -51.58 while comparing to the previous closing price of $5.39. In past 52 weeks, the stock remained buoying in the range of price level as high as $11.90 and as low as $4.69. In the recent trading on the day, stock has struck highest price mark of $2.51 while lowest mark touched by it was $4.42.
Taking a look at 20-day trading activity of Acrivon Therapeutics Inc (ACRV) gives us an average price of $5.24, while its current price level is -78.07% below from 52-week high level whereas it is -44.35% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $5.48 while that of 200 days or SMA-200 reads an average of $6.93. A closer look into the stock’s movement over the week reveals that its volatility is standing at 20.83% during that period while stretching the period over a month that decreases to 9.75%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 24.13 which implies that the stock is in oversold territory.
Ladenburg Thalmann upgraded its recommendation for the stock as a “Buy” from “Neutral” on September 16, 2024 while assigning a price target of $16.
Over the week, ACRV’s stock price is moving -52.20% down while it is -52.80% when we observe its performance for the past one month. Year-to-date it is -56.64% down and over the past year, the stock is showing a downside performance of -57.84%.
The company is expected to be releasing its next quarterly report on 2024-Nov-12, for which analysts forecasted an EPS of -0.7 while estimate for next year EPS is -2.6.
Currently, Acrivon Therapeutics Inc’s total number of outstanding shares is 31.13M with 22.06% of that held by the insiders while 74.98% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -38.51% and return on equity (ROE) at -45.95%. Stock’s beta reads 0.80. Stock has a price to book (P/B) ratio of 0.41. Its return on asset (ROA) is -42.09% on average.
